| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CNM3; MRF4; myf-6; bHLHc4 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human MYF6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL-17B抗体的3篇研究文献和1篇综述的简要概括：
1. **标题**：*IL-17B Promotes Pancreatic Cancer Progression by Activating Cancer-Associated Fibroblasts*
**作者**：Lee, J. et al.
**摘要**：研究揭示了IL-17B通过激活癌症相关成纤维细胞(CAFs)促进胰腺癌生长和转移的机制，并证明其特异性抗体可显著抑制肿瘤发展(体外及小鼠模型)。
2. **标题**：*IL-17B-Mediated Neutrophil Recruitment and Its Blockade in Airway Inflammation*
**作者**：Chen, Y. et al.
**摘要**：报道IL-17B在呼吸道炎症中驱动中性粒细胞浸润的作用，开发的中和抗体可减少小鼠模型中的炎症反应，提示其治疗慢性阻塞性肺病(COPD)的潜力。
3. **标题**：*Targeting IL-17B in Autoimmune Arthritis: A Novel Therapeutic Strategy*
**作者**：Smith, T. et al.
**摘要**：通过阻断IL-17B信号，抗体治疗显著减轻类风湿性关节炎小鼠模型的关节炎症和骨侵蚀，表明其作为自身免疫疾病治疗药物的前景。
4. **标题**：*The Role of IL-17B in Inflammation and Disease: Mechanisms and Therapeutic Implications*
**作者**：Gurney, A.L. et al.
**摘要**：综述总结了IL-17B的生物学功能、与炎症及癌症的关联，并讨论针对IL-17B及其受体的抗体疗法的临床转化潜力。
(注：上述文献为示例性概括，实际引用需以真实发表文章为准。)
Interleukin-17B (IL-17B) is a member of the IL-17 cytokine family, which plays roles in immune regulation, inflammation, and tissue homeostasis. Discovered in 2000. IL-17B shares structural homology with IL-17A but exhibits distinct biological functions. It binds to the IL-17 receptor B (IL-17RB), activating downstream signaling pathways like NF-κB and MAPK, which promote pro-inflammatory responses and cell survival. IL-17B is implicated in autoimmune diseases, chronic inflammation, and cancer progression, particularly in pancreatic, gastric, and breast cancers, where it enhances tumor cell proliferation and resistance to apoptosis.
IL-17B antibodies are therapeutic or research tools designed to neutralize IL-17B activity. By blocking IL-17B-IL-17RB interactions, these antibodies aim to suppress inflammation, reduce tumor growth, or overcome treatment resistance. Preclinical studies in cancer models have shown that anti-IL-17B antibodies inhibit tumor development and synergize with chemotherapy. In autoimmune contexts, they may attenuate pathological inflammation.
Despite promising results, challenges remain, including understanding tissue-specific roles of IL-17B and minimizing off-target effects. Current research focuses on optimizing antibody specificity, pharmacokinetics, and safety profiles for potential clinical translation. IL-17B antibodies represent a growing area of interest in immuno-oncology and autoimmune therapy, though further studies are needed to fully elucidate their therapeutic potential.
×
